Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biophytis Sa ADR (NQ: BPTS ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Biophytis Sa ADR < Previous 1 2 3 Next > Biophytis is Deploying its Partnership Strategy in Obesity April 29, 2024 Via ACCESSWIRE Biophytis Announces Transfer of ADSs to OTC Market April 24, 2024 Via ACCESSWIRE Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program April 18, 2024 Via ACCESSWIRE Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity April 17, 2024 Via ACCESSWIRE Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities April 08, 2024 Via ACCESSWIRE Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) April 08, 2024 Via ACCESSWIRE Results of the Combined General Meeting on April 2, 2024 April 04, 2024 Via ACCESSWIRE Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted June 16, 2023 Via ACCESSWIRE Biophytis Announces Receipt of Nasdaq Notice November 17, 2023 Via ACCESSWIRE Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil October 30, 2023 Via ACCESSWIRE Biophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings Panel October 27, 2023 Via ACCESSWIRE Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations September 27, 2023 Via ACCESSWIRE Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise September 26, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END Via FinancialNewsMedia Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) September 25, 2023 Via ACCESSWIRE Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19 September 19, 2023 Via ACCESSWIRE Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer September 14, 2023 Via ACCESSWIRE Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia September 11, 2023 Via ACCESSWIRE Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York September 04, 2023 Via ACCESSWIRE Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project August 16, 2023 Via ACCESSWIRE Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe August 08, 2023 Via ACCESSWIRE Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19 July 20, 2023 Via ACCESSWIRE Biophytis Announces $3.8 Million Registered Direct Offering July 19, 2023 Via ACCESSWIRE Russell 2000 ETF Momentum Sparks Volatility In Small Caps July 18, 2023 The iShares Russell 2000 ETF (NYSE: IWM) impressive upward momentum has led to a volume, attention, and volatility surge in the small-cap market. Via MarketBeat Topics ETFs Initial Public Offering Exposures Securities Market Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound July 18, 2023 Via ACCESSWIRE Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia July 10, 2023 Via ACCESSWIRE Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress June 19, 2023 Via ACCESSWIRE Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June June 05, 2023 Via ACCESSWIRE Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19 May 26, 2023 Via ACCESSWIRE Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference May 25, 2023 Via ACCESSWIRE Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia May 15, 2023 Via ACCESSWIRE < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
